文献速递腹部泌尿生殖CTMRUS

预测胰腺导管内乳头状黏液性肿瘤恶性潜能的诊断效能与影像特征:超声内镜、增强CT与MRI的比较

Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI.
PubMed 文献 · Abdom Radiol (NY) · 2017-01-01

研究纳入76例胰腺导管内乳头状黏液性肿瘤患者(良性37例、恶性39例),比较超声内镜、增强CT与MRI预测恶性潜能的诊断效能。三种方法AUC分别为增强CT 0.792(阅片者1)与0.830(阅片者2)、MRI 0.742(阅片者1)与0.776(阅片者2)、超声内镜0.733,差异无统计学意义(P>0.05)。多因素分析显示增强CT与MRI上的强化实性成分、超声内镜上的壁结节、主胰管直径≥10 mm、主胰管直径5–9 mm及囊壁/分隔增厚为显著变量。

要点

  • 增强CT、MRI与超声内镜预测IPMN恶性潜能的AUC分别为0.733–0.830,三者差异无统计学意义。
  • 强化实性成分、壁结节、主胰管直径≥10 mm、主胰管直径5–9 mm及囊壁/分隔增厚为恶性相关显著变量。
  • 囊壁/分隔增厚与主胰管管径突然改变的阅片者间一致性较低(k=0.579–0.788)。

核心结论

  • 增强CT、MRI与超声内镜预测胰腺IPMN恶性潜能的诊断效能相当,各 modality 间差异无统计学意义。

研究设计与样本

  • 比较性研究,纳入76例IPMN患者(良性37例、恶性39例),均行超声内镜、增强CT与MRI;超声内镜依据正式报告分析,增强CT与MRI由两名放射科医师依据2012年共识指南回顾性分析。

关键影像表现/征象

  • 增强CT与MRI上强化实性成分、超声内镜上壁结节为恶性IPMN的显著相关变量(OR:CT 1.8、MRI 1.36、超声内镜1.47)。
  • 主胰管直径≥10 mm在增强CT(OR 1.3)、MRI(OR 1.4)与超声内镜(OR 1.66)均为显著变量。
  • 主胰管直径5–9 mm在增强CT(OR 1.23)与MRI(OR 1.31)为显著变量。
  • 囊壁/分隔增厚在增强CT与MRI为显著变量(OR 1.3)。

诊断标准与关键数值

  • 增强CT预测恶性IPMN的AUC为0.792(阅片者1)与0.830(阅片者2)。
  • MRI预测恶性IPMN的AUC为0.742(阅片者1)与0.776(阅片者2)。
  • 超声内镜预测恶性IPMN的AUC为0.733。
  • 三种方法AUC比较差异无统计学意义(P>0.05)。
  • 囊壁/分隔增厚的阅片者间一致性k=0.579–0.617,主胰管管径突然改变k=0.689–0.788,其他变量k>0.80。

临床应用与阅片要点

  • 阅片时应关注强化实性成分、壁结节、主胰管直径≥10 mm、主胰管直径5–9 mm及囊壁/分隔增厚等与恶性潜能相关的影像特征。
  • 囊壁/分隔增厚与主胰管管径突然改变的阅片者间一致性相对较低,报告时需注意判读的一致性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare diagnostic performance for prediction of malignant potential in IPMNs between EUS, contrast-enhanced CT and MRI.

MATERIALS AND METHODS: 76 patients with IPMN (benign = 37, malignant = 39) underwent EUS, contrast-enhanced CT, and MRI. EUS was analyzed based on formal reports and contrast-enhanced CT and MRI were retrospectively analyzed by two radiologists according to the consensus guidelines 2012. Diagnostic performance and imaging features of malignant IPMNs were analyzed using ROC analysis and multivariate analyses.

RESULTS: Diagnostic performance of contrast-enhanced CT (AUC = 0.792 in R1, 0.830 in R2), MRI (AUC = 0.742 in R1, 0.776 in R2), and EUS (AUC = 0.733) for predicting malignant IPMNs were comparable without significant difference (p > 0.05). In multivariable analysis, enhancing solid component in contrast-enhanced CT and MRI and mural nodule in EUS (OR 1.8 in CT, 1.36 in MRI, 1.47 in EUS), MPD diameter ≥ 10 mm (OR 1.3 in CT, 1.4 in MRI, 1.66 in EUS), MPD diameter of 5-9 mm (OR 1.23 in CT, 1.31 in MRI), and thickened septa or wall (OR 1.3 in CT and MRI) were significant variables (p < 0.05). Interobserver agreement of thickened cyst septa or wall (k = 0.579-0.617) and abrupt caliber change of MPD (k = 0.689-0.788) was lower than other variables (k > 0.80).

CONCLUSION: Diagnostic performance of contrast-enhanced CT, MRI, and EUS for predicting malignant IPMNs was comparable with each modalities without significant difference.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Choi SY, Kim JH, Yu MH, et al. Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI. Abdom Radiol (NY). 2017. PMID: 28144718. doi:10.1007/s00261-017-1053-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。